Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

62.20 +0.06 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,461,715
Open 62.22
Bid (Size) 59.03 (1)
Ask (Size) 64.00 (1)
Prev. Close 62.14
Today's Range 61.63 - 63.30
52wk Range 33.31 - 63.30
Shares Outstanding 62,107,572
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews
 
Via Benzinga
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis. 
Via Benzinga

Performance

YTD
+59.6%
+59.6%
1 Month
+10.6%
+10.6%
3 Month
+16.6%
+16.6%
6 Month
+18.1%
+18.1%
1 Year
+35.5%
+35.5%

More News

Read More
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Via ACCESS Newswire
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Via ACCESS Newswire
9 Analysts Assess Protagonist Therapeutics: What You Need To Know
Via Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Via Benzinga
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Via ACCESS Newswire
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Via ACCESS Newswire
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Via ACCESS Newswire
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics
Via Benzinga
Protagonist (PTGX) Q2 Revenue Falls 26%
Via The Motley Fool
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
Via ACCESS Newswire
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Via Investor's Business Daily
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Via ACCESS Newswire
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Via ACCESS Newswire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Via ACCESS Newswire
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why.
Via Chartmill
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Via Benzinga
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Via ACCESS Newswire
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
Via ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESS Newswire

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 62.20
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 09/19/25 04:00 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 3.86B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.